Amantadine augmentation therapy for obsessive compulsive patients resistant to SSRIs - an open-label study

Clinical Neuropharmacology

Volumn 37, Issue 3, 2014, Pages 79-81

  Stryjer, Rafael ^a,b   Budnik, Dana ^a   Ebert, Tania ^a   Green, Tamar ^a   Polak, Lea ^b,c   Weizman, Shira ^d   Spivak, Baruch ^a,b  

^a NESS ZIONA MENTAL HEALTH CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c ASSAF HAROFEH MEDICAL CENTER   (Israel)

^d MEIR MEDICAL CENTER   (Israel)

Author keywords

amantadine; glutamate; obsessive compulsive disorder (OCD); selective serotonin reuptake inhibitors (SSRI)

Indexed keywords

ACETYLSALICYLIC ACID; AMANTADINE; CITALOPRAM; ESCITALOPRAM; FLUVOXAMINE; METFORMIN; PAROXETINE; SALBUTAMOL; SEROTONIN UPTAKE INHIBITOR; SIMVASTATIN; DOPAMINE RECEPTOR STIMULATING AGENT; N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

ADULT; ANXIETY; ARTICLE; BEDTIME DOSAGE; CLINICAL ARTICLE; COMPULSION; DEPRESSION; DSM-IV-TR; FEMALE; HAMILTON ANXIETY SCALE; HAMILTON SCALE; HUMAN; MALE; OBSESSION; OBSESSIVE COMPULSIVE DISORDER; OPEN STUDY; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; TREATMENT DURATION; YALE BROWN OBSESSIVE COMPULSIVE SCALE; AGED; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG COMBINATION; DRUG RESISTANCE; MIDDLE AGED; OBSESSIVE-COMPULSIVE DISORDER; PATIENT DROPOUTS; PSYCHOLOGICAL RATING SCALE; YOUNG ADULT;

ADULT; AGED; AMANTADINE; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DOPAMINE AGONISTS; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; OBSESSIVE-COMPULSIVE DISORDER; PATIENT DROPOUTS; PSYCHIATRIC STATUS RATING SCALES; RECEPTORS, N-METHYL-D-ASPARTATE; SEROTONIN UPTAKE INHIBITORS; YOUNG ADULT;

EID: 84901346281     PISSN: 03625664     EISSN: 1537162X     Source Type: Journal    
DOI: 10.1097/WNF.0000000000000029     Document Type: Article

References (32)

1. Ison MG. Clinical use of approved influenza antivirals: Therapy and prophylaxis. Influenza Other Respir Viruses 2013;7(Suppl 1):7-13
2. Huber TJ, Dietrich DE, Emrich HM. Possible use of amantadine in depression. Pharmacopsychiatry 1999;32:47-55. (Pubitemid 29197549
3. Pud D, Eisenberg E, Spitzer A, et al. The NMDA receptor amantadine antagonist reduces surgical neuropathic pain in cancer patients: A double blind, randomized, placebo controlled trial. Pain 1998;75:349-354. (Pubitemid 28160146
4. Stryjer R, Strous RD, Shaked G, et al. Amantadine as augmentation therapy in the management of treatment-resistant depression. Int Clin Psychopharmacol 2003;18:93-96. (Pubitemid 36343978
5. Starck G, Ljungberg M, Nilsson M, et al. A 1H magnetic resonance spectroscopy study in adults with obsessive compulsive disorder: Relationship between metabolites concentrations and symptom severity. J Neural Transm 2008;115:1051-1062
6. Rosenberg DR, Keshavan MS. A.E. Bennett Research award. Toward a neurodevelopmantal model of obsessive-compulsive disorder. Biol Psychiatry 1998; 43:623-640
7. Chakrabarty K, Bhattacharyya S, Christopher R, et al. Glutamatergic dysfunction in OCD. Neuropsychopharmacology 2005;30:1735-1740. (Pubitemid 43086030
8. Rotge JY, Guehl D, Dilharreguy B, et al. Meta-Analysis of brian volume changrs in obsessive-compulsive disorder. Biol Psychiatry 2009;65:75-83
9. Pittenger C, krystal JH, Coric V. Glutamate - modulating drugs as novel pharmacotherapeutic agents in the treatment of obsessive - compulsive disorder. Neuro Rx 2006;3:69-81
10. Coric V, Taskiran S, Pittenger C, et al. Riluzole augmentation in treatment - resistant obsessive-compulsive disorder: An open - label trial. Biol Psychiatry 2005;58:424-428. (Pubitemid 41219711
11. Grant P, Lougee L, Hirschtritt M, et al. An open - label trial of riluzole, a glutamate antagonist, in children with treatment - resistant obsessive - compulsive disorder. J Child Adolesc Psychopharmacol. 2007; 17:761-767. (Pubitemid 351158597
12. Lafleur DL, Pittenger C, Kelmendi B, et al. N-Acetylcysteine augmentation in serotonin reuptake inhibitor refractory obsessive-compulsive disorder. Psychopharmacology (Berl) 2006;184:254-256. (Pubitemid 43084809
13. Kushner MG, Kim SW, Donahue C, et al. D - cycloserine augmentated exposure therapy for obsessive - compulsive disorder. Biol Psychiatry 2007;62:835-838. (Pubitemid 47488217
14. Poyurovsky M, Weizman R, Weizman A, et al. Memantine for treatment-resistant OCD. Am J Psychiatry 2005;162:2191-2192
15. Pasquini M, Biondi M. Memantine augmentation for refractory obsessive-compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2006;30:1173-1175. (Pubitemid 43928231
16. Aboujaoude E, Barry JJ, Gamel N. Memantine augmentation in treatment - resistant obsessive - compulasive disorder: An open label trial. J Clin Psychopharmacol 2009;29:51-55
17. Feusner JD, Kerwin L, Saxena S, et al. Differential efficacy of memantine for obsessive - compulsive disorder vs. generalized anxiety disorder: An open - label trial. Psychophamacol Bull 2009;42: 81-93
18. Ghaleiha A, Entezari N, Modabbernia A, et al. Akhon: Memantine add-on in moderate to severe obsessive-compulsive disorder; randomized double-blind placebo-controlled study. J Psychiatr Res 2013;47:175-180
19. Haghighi M, Jahangard L, Mohammad-Beigi H, et al. In a double blind, randomized and placebo-controlled trial, adjuvant memantine improved symptoms in inpatients suffering from refractory obsessive-compulsive disorder (OCD). Psychopharmacology (Berl) 2013;228:633-640
20. Greenberg WM, Benedict MM, Doerfer J, et al. Adjunctive glycine in the treatment of obsessive - compulsive disorder in adults. J Psychiatr Res 2008;43:664-670
21. Pasquini M, Berardeli I, Biondi M. Amantadine augmentation for refractory obsessive-compulsive disorder -A case report. J Clin Psychopharmacol 2010;30:85-86
22. Blanpied TA, Clarke RJ, Johnson JW. Amantadine inhibits NMDA receptors by accelerating channel closure during channel block. J Neurosci 2005;25:3312-3322. (Pubitemid 40471340
23. Onogi H, Ishigaki S, Nakagawasai O, et al. Influence of memantine on brain monoaminergic neurotransmission parameters in mice: Neurochemical and behavioral. Biol Pharm Bull 2009;32:850-855
24. Arnold PD, Sicard T, Burroughs E, et al. Glutamate transporter gene SLC1A1 associated with obsessive-compulsive disorder. Arch Gen Psychiatry 2006;63:769-776
25. Ruscio AM, Stein DJ, Chiu WT, et al. The epidemiology of obsessive-compulsive disorder in the National Comorbidity Survey Replication. Mol Psychiatry 2010;15:53-63
26. Mataix-Cols D, Wooderson S, Lawrence N, et al. Distinct neural correlates of washing, checking, and hoarding symptom dimensions in obsessive-compulsive disorder. Arch Gen Psychiatry 2004;61:564-576. (Pubitemid 38747311
27. van den Heuvel OA, Remijnse PL, Mataix-Cols D, et al. The major symptom dimensions of obsessive-compulsive disorder are mediated by partially distinct neural systems. Brain 2009;132(Pt 4):853-868
28. Landeros-Weisenberger A, Bloch MH, Kelmendi B, et al. Coric Dimensional predictors of response to SRI pharmacotherapy in obsessive-compulsive disorder. J Affect Disord 2010;121:175-179
29. Pittenger C, Krystal JH, Coric V. Glutamate-modulating drugs as novel pharmacotherapeutic agents in the treatment of obsessive-compulsive disorder. NeuroRx 2006;3:69-81. (Pubitemid 43276634
30. Carlsson ML. On the role of prefrontal cortex glutamate for the antithetical phenomenology of obsessive compulsive disorder and attention deficit hyperactivity disorder. Prog Neuropsychopharmacol Biol Psychiatry 2001;25:5-26. (Pubitemid 32173787
31. Ting JT, Feng G. Glutamatergic synaptic dysfunction and obsessive-compulsive disorder. Curr Chem Genomics 2008;2:62-75
32. Chakrabarty K, Bhattacharyya S, Christopher R, et al. Glutamatergic dysfunction in OCD. Neuropsychopharmacology 2005;30:1735-1740. (Pubitemid 43086030